Mortality after a cerebrovascular event in age-related macular degeneration patients treated with bevacizumab ocular injections.

We found increased mortality within three months after a cerebrovascular event in patients treated with bevacizumab for AMD compared to patients for whom there was no record of a prescription to any anti-VEGF agent.